Immunodeficient LP-BM5 virus infected mice (MAIDS) fail to develop long-term marrow cultures (LTMC) in vitro, effect of zidovudine (AZT) (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Immunodeficient LP-BM5 virus infected mice (MAIDS) fail to develop long-term marrow cultures (LTMC) in vitro, effect of zidovudine (AZT) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 34:A549 1993. Unique Identifier : AIDSLINE MED/93694210
Gallicchio VS; Tse KF; Hughes NK; Univ. of Kentucky, Lexington, KY 40536

Abstract: We report results of studies examining the ability of AZT to influence the development of LTMC using marrow from normal or MAIDS-infected mice. Normal C57BL6 mice were infected with LP-BM5 MuLV) immunodeficiency virus (10 ug total protein) ip. 5-wk after viral infection, mice were sacrificed and marrow harvested from normal nonvirus infected and virus control mice. LTMC were established in the presence or absence of dose escalation AZT, ie, 10(-6) M, 5 x 10(-7) M, or 10(-7) M in vitro. Compared to normal controls, LTMC using MAIDS-infected marrow failed to produce supernatant derived mononuclear cells which were further reduced in the presence of AZT. Erythroid (BFU-E), myeloid CFU-GM), and megakaryocyte (CFU-Meg) progenitor stem cells were all reduced and none were observed after 5-wk culture. AZT failed to reverse this depression. Microscopic examination of cultures at 10 wk demonstrated failed stromal layer development from MAIDS-cultures compared to nonvirus controls. These results indicate the marrow hypoplasia associated with HIV-infection may be due in part to the inadequate establishment of a normal hematopoietic microenvironment/stroma that is not improved with AZT.
Keywords: *Hematopoietic Stem Cells/PATHOLOGY *Murine Acquired Immunodeficiency Syndrome/PATHOLOGYKWDhematopoieticstemcells/pathologyKWDmurineacquiredimmunodeficiencysyndrome/pathology
931130
M93B5835

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .